Dalotuzumab

Drug Profile

Dalotuzumab

Alternative Names: Anti-IGF-1 receptor monoclonal antibody - Pierre Fabre; Anti-IGF-1R monoclonal antibody - Pierre Fabre; F 50 035; h7C10; MK-0646

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Developer Merck & Co
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer
  • Phase I/II Pancreatic cancer
  • No development reported Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 26 Jul 2015 Dalotuzumab is still in phase II trials for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the USA, Belgium, Canada, Columbia, Denmark, Germany, Israel, Italy, Peru, Spain, Sweden, South Korea, Taiwan and United Kingdom
  • 26 Jul 2015 Dalotuzumab is still in phase I/II trials for Pancreatic cancer in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top